Abstract
Growth Arrest Specific1 (Gas1) is a protein expressed during development and when cells arrest their growth. The potential of Gas1 as an adjuvant in the treatment of cancer, and its role as a tumor suppressor have also been proposed. We had previously demonstrated the structural relationship between Gas1 and the α receptors for the Glial-cell line-Derived Neurotrophic Factor (GDNF) family of ligands, and showed that Gas1 acts by inhibiting the intracellular signaling induced by GDNF, reducing both the pattern of autophosphorylation of Ret and the activation of AKT, thus inducing cell arrest and apoptosis. On the other hand, it has also been proposed that Gas1 positively interacts with Sonic Hedgehog (Shh) during embryonic development. In this review we will critically evaluate the data regarding the molecular mechanisms of action of Gas1, and discuss that the potential therapeutic effects of Gas1 treating cancer are related with its capacity inhibiting the intracellular signaling cascade induced by GDNF.
Keywords: Gas1, GDNF, Shh, Glioma, AKT, apoptosis, NIH-3T3 mouse cells, retrotransposon, chromosome 9q21.3-22.1., glycosil phosphatydilinositol, GFRs, NIH-3T3, lung adenocarcinoma, C6 murine glioma, U373 human glioma, primary cultures of human, cultures of hippocampal neurons, neuroblastoma, corpus luteum, methionine deprivation, chemopreventive agent (Green tea catechins), epirubicin, granule cells, Bergman glia fibers, microphthalmia, microform holoprosen-cephaly, multiple craniofacial defects, p53, Rb, B49 cells, neurturin (NRTN), artemin (ARTN), persephin (PSPN), tyrosine kinase, GFR1-4, GFR1, GFR2, GFR3, PSPN, Ret9, Ret43, Ret51, Shc, FRS2, DOK4/5, IRS1/2, enigma, MEN2A, familiar medullary thyroid carcinoma (FMTC), MEN2B, Yes-associate protein (YAP)
Current Signal Transduction Therapy
Title: Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Volume: 6 Issue: 1
Author(s): Gabriela Dominguez-Monzon, Ricardo Gonzalez-Ramirez and Jose Segovia
Affiliation:
Keywords: Gas1, GDNF, Shh, Glioma, AKT, apoptosis, NIH-3T3 mouse cells, retrotransposon, chromosome 9q21.3-22.1., glycosil phosphatydilinositol, GFRs, NIH-3T3, lung adenocarcinoma, C6 murine glioma, U373 human glioma, primary cultures of human, cultures of hippocampal neurons, neuroblastoma, corpus luteum, methionine deprivation, chemopreventive agent (Green tea catechins), epirubicin, granule cells, Bergman glia fibers, microphthalmia, microform holoprosen-cephaly, multiple craniofacial defects, p53, Rb, B49 cells, neurturin (NRTN), artemin (ARTN), persephin (PSPN), tyrosine kinase, GFR1-4, GFR1, GFR2, GFR3, PSPN, Ret9, Ret43, Ret51, Shc, FRS2, DOK4/5, IRS1/2, enigma, MEN2A, familiar medullary thyroid carcinoma (FMTC), MEN2B, Yes-associate protein (YAP)
Abstract: Growth Arrest Specific1 (Gas1) is a protein expressed during development and when cells arrest their growth. The potential of Gas1 as an adjuvant in the treatment of cancer, and its role as a tumor suppressor have also been proposed. We had previously demonstrated the structural relationship between Gas1 and the α receptors for the Glial-cell line-Derived Neurotrophic Factor (GDNF) family of ligands, and showed that Gas1 acts by inhibiting the intracellular signaling induced by GDNF, reducing both the pattern of autophosphorylation of Ret and the activation of AKT, thus inducing cell arrest and apoptosis. On the other hand, it has also been proposed that Gas1 positively interacts with Sonic Hedgehog (Shh) during embryonic development. In this review we will critically evaluate the data regarding the molecular mechanisms of action of Gas1, and discuss that the potential therapeutic effects of Gas1 treating cancer are related with its capacity inhibiting the intracellular signaling cascade induced by GDNF.
Export Options
About this article
Cite this article as:
Dominguez-Monzon Gabriela, Gonzalez-Ramirez Ricardo and Segovia Jose, Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications, Current Signal Transduction Therapy 2011; 6 (1) . https://dx.doi.org/10.2174/157436211794109433
DOI https://dx.doi.org/10.2174/157436211794109433 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry Targeting Focal Adhesion Kinase in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Current Medicinal Chemistry Nanoparticulate Formulations for Paclitaxel Delivery Across MDCK Cell Monolayer
Current Pharmaceutical Design Nanotools for the Delivery of Antimicrobial Peptides
Current Drug Targets Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Pro-Oxidant Milieu Blunts Scissors: Insight into Tumor Progression, Drug Resistance, and Novel Druggable Targets
Current Pharmaceutical Design Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors
Current Medicinal Chemistry NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme
Current Pharmacogenomics and Personalized Medicine Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Patent Selections
Recent Patents on Biotechnology A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets Ferroptosis Inducers for Prostate Cancer Therapy
Current Medicinal Chemistry